Fig. 5

GPER1 promoted SREBP1-SCD1 via PI3K/AKT/mTOR signaling. (A, B) The activation of PI3K/AKT/mTOR signaling (the protein levels of p-PI3K, p-AKT, and p-mTOR) in the GPER1-overexpressing or knockdown cells. (C) The activation of PI3K/AKT/mTOR signaling (the protein levels of p-PI3K, p-AKT, and p-mTOR) in A549 and H1299 cells treated with G1 for 24 and 48 h. (D) The levels of SREBP1 (fl.), SREBP1 (p), and SCD1 and the activation of PI3K/AKT/mTOR signaling (the protein levels of p-PI3K, p-AKT, and p-mTOR) were determined in A549 and H1299 cells that were treated with G1, PI3K(i) (NSC781406), or both for 48 h. (E) The fluorescence of BODIPY 581/591C11 in A549 and H1299 cells that were treated with G1, PI3K(i) (NSC781406), or both for 48 h, as analyzed using flow cytometry. (F) MDA levels in the A549 and H1299 cells that were treated with G1, PI3K(i) (NSC781406), or both for 48 h. (G) The viability of A549 and H1299 cells that were treated with G1, PI3K(i) (NSC781406), or both for 48 h, determined using the CCK8 assay. The results are presented as the mean ± SD. n = 3; *P < 0.05, **P < 0.01, ***P < 0.001